CRD 2015
Alternative Names: CRD-2015Latest Information Update: 26 Dec 2023
At a glance
- Originator Cardurion Pharmaceuticals
- Class Cardiovascular therapies; Heart failure therapies; Heterocyclic compounds
- Mechanism of Action Calcium-calmodulin-dependent protein kinase type 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cardiovascular disorders; Heart failure
Most Recent Events
- 11 Nov 2023 Pharmacodynamics data from preclinical studies in Heart failure presented at the American Heart Association Scientific Sessions 2023 (AHA-2023)
- 10 Nov 2023 Pharmacodynamics data from a preclinical study in Heart failure released by Cardurion Pharmaceuticals
- 07 Nov 2023 Cardurion Pharmaceuticals plans clinical development of CRD-2015